Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia
October 23, 2017 07:30 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or the “Company”) today announced the enrollment of the first patient in the pivotal Part 2 of the...
Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting
October 20, 2017 11:02 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or the “Company”) announced that the primary efficacy and safety data from the Phase 2 portion of...
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma
September 13, 2017 17:26 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that the United...
Reata Pharmaceuticals, Inc. Announces Second Quarter 2017 Financial and Operating Results
August 14, 2017 16:01 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced financial results...
FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia
August 14, 2017 07:00 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food...
Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
August 07, 2017 17:14 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or the “Company”) today announced the enrollment of the first patient in the Phase 3 portion of...
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 01, 2017 10:28 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its...
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering
July 26, 2017 19:17 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, July 26, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an...
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
July 25, 2017 16:04 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, July 25, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to...
Reata’s Bardoxolone Methyl Demonstrated Improved Kidney Function in Patients With Alport Syndrome in Ongoing Phase 2 Portion of Phase 2/3 Cardinal Study
July 24, 2017 07:00 ET
|
Reata Pharmaceuticals, Inc.
SCREENING OF PATIENTS IN PHASE 3 PORTION OF CARDINAL UNDERWAYPLANNING TO INITIATE ADDITIONAL RARE CHRONIC KIDNEY DISEASE PROGRAMSCONFERENCE CALL WITH MANAGEMENT SCHEDULED TODAY AT 8:30AM ET IRVING,...